Latest news with #Pen-G
Business Upturn
13 hours ago
- Business
- Business Upturn
Nuvama bullish on Aurobindo Pharma, sees 15% profit CAGR through FY27
By Markets Desk Published on June 20, 2025, 07:30 IST Nuvama Institutional Equities has reiterated a 'Buy' call on Aurobindo Pharma, with a target price of ₹1,460, as it sees the stock poised for a strong recovery led by new product launches, capacity expansions, and normalization of regulatory and operational issues. The brokerage notes that Aurobindo has invested over ₹10,000 crore in recent years toward growth-oriented assets including its Pen-G API facility, injectable plants, and biologics and peptide capabilities. While these investments have temporarily diluted return ratios, Nuvama believes they position the company strongly for medium- to long-term growth, especially in high-margin, non-oral dosage categories. Key triggers that could unlock value in FY26–27 include: Resumption of production at its Pen-G unit , which could improve vertical integration and cost competitiveness. New launches in Europe from the company's Chinese facility. Ramp-up of injectables business through the Eugia-5 plant and normalization of supply issues from Eugia-3. Volume growth in oral solids, which continue to be the company's bread and butter in regulated markets like the US. Nuvama is building in a revenue CAGR of 7%, EBITDA CAGR of 8%, and PAT CAGR of 15% over FY25–27. Despite the recent recovery in pharma stocks, Aurobindo continues to trade at 13.9x FY27E EPS, which represents a 16% discount to its 5-year historical average valuation. This makes the stock attractive not only from a growth and margin recovery standpoint but also on relative valuation terms, especially considering that many of its operational headwinds now appear to be easing. Aurobindo has also stepped up its focus on specialty and complex generics, including biosimilars, peptides, and depot injections, which can provide earnings durability beyond FY27. The company's recent USFDA approvals and steady ANDA filings also indicate improving regulatory momentum. Nuvama's thesis remains that execution of these strategic pivots—especially monetization of recent capex—could drive a meaningful re-rating of the stock over the next 6–8 quarters. Ahmedabad Plane Crash Markets Desk at
Time of India
30-05-2025
- Business
- Time of India
I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330
ICICI Securities has downgraded Aurobindo Pharma to 'Add' with a revised target price of Rs 1,330, citing potential decline in gRevlimid sales due to pricing competition and a temporary halt in Pen-G plant production. While Europe business shows promise with new launches and biosimilars, lowered FY26/27E EBITDA reflects anticipated lower sales from Eugia. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads (Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of Please consult your financial adviser before taking any position in the stock/s mentioned.)
Time of India
28-04-2025
- Business
- Time of India
Fire incident forces Aurobindo arm Lyfius to temporarily pause Pen-G production at Kakinada plant
HYDERABAD : In a setback for Aurobindo Pharma , the company has temporarily paused production at its subsidiary, Lyfius Pharma Pvt Ltd's Penicillin-G manufacturing plant at Kakinada in Andhra Pradesh after a fire broke out at the facility on Sunday night. 'The incident resulted in damage to certain ancillary equipment, with no impact to the core manufacturing infrastructure. Importantly there were no injuries reported,' Aurobindo Pharma said in a regulatory filing on Monday evening. 'As a temporary measure and to facilitate necessary equipment replacements, operations at the plant will be temporarily paused for an estimated period for 20 to 25 days. A thorough assessment of the damage is currently underway,' the company said. However, Aurobindo Pharma said the incident is not expected to have any material impact on the operations or financials of the group as the facility is fully insured. The fire broke out at around 10pm on April 27, 2025, in the vicinity of the coal crusher area of the Pen-G facility. 'The fire incident took place due to self-ignition of coal. We are in the process of ascertaining the exact reasons for the same,' the company said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Click Here - This Might Save You From Losing Money Expertinspector Click Here Undo The 15,000 metric tonnes per annum capacity plant was set up at an investment of Rs 2,500 crore under the Indian govt's production linked incentive (PLI) scheme for key starting materials, drug intermediates and active pharmaceutical ingredients (APIs). The plant, which makes Pen-G for the domestic and exports market, became operational in April 2024 but was formally inaugurated by Prime Minister Narendra Modi virtually in October 2024 end. Stay informed with the latest business news, updates on bank holidays and public holidays . Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!
